Company intelligence / Profile preview

Core Biogenesis

Ownership: Private
Development stage: Preclinical

Overview

Core Biogenesis has developed a proprietary plant-based bioproduction technology to manufacture high-value recombinant proteins—primarily animal-free, endotoxin-free growth factors—for use in life sciences research, regenerative medicine manufacturing, cultivated meat production, and skincare. Their products are commercially available but are not themselves therapeutics with clinical trial results.

Therapeutic areas: OtherDermatology
Modalities: Recombinant proteinPeptidesCytokine (growth factors)Protein
Industry: Non-Drug Biotech

Partnerships

Not specifically listed in public sources as of June 2025.

Beyond the preview

Go deeper on Core Biogenesis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Core Biogenesis.

Explore the full profile